progen pharmaceuticals, page-2

If you did not read the previous post in full then at least read this bit:


“Our assessment of data generated by the two drugs suggests that PI-88 has a better side effect profile than Nexavar at therapeutic concentrations making it the better suited of the two as a long-term therapy to prevent tumour recurrence. This could be an important differentiator between the two compounds should Bayer\Onyx decide to pursue a phase-III study of Nexavar in post resection patients.

We maintain our BUY recommendation on Progen with valuation of A$16.45 per share.


No porky telling here !